Charles Moore
Stock Analyst at Robert W. Baird
(3.27)
# 2,641
Out of 4,683 analysts
8
Total ratings
87.5%
Success rate
22.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Moore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintained: Buy | $34 | $24.57 | +38.38% | 3 | Aug 7, 2026 | |
| CTNM Contineum Therapeutics | Maintained: Buy | $14 → $20 | $17.02 | +17.51% | 2 | Mar 6, 2026 | |
| DRUG Bright Minds Biosciences | Maintained: Buy | $142 → $126 | $76.63 | +64.43% | 3 | Feb 13, 2026 |
Denali Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $34
Current: $24.57
Upside: +38.38%
Contineum Therapeutics
Mar 6, 2026
Maintained: Buy
Price Target: $14 → $20
Current: $17.02
Upside: +17.51%
Bright Minds Biosciences
Feb 13, 2026
Maintained: Buy
Price Target: $142 → $126
Current: $76.63
Upside: +64.43%